Evidence map›Paper›PMID 41045314›Full record

ArticleJournal of molecular modeling2025

In silico identification of anticancer flavonoids as dengue virus replication inhibitors: a molecular docking and simulation approach.

Soumendu Patra, Arindam Paul, Harshita Shand, Sayan Ghosal, Suvankar Ghorai

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Soumendu PatraInfection and Disease Biology Laboratory, Department of Microbiology, Raiganj University, Raiganj, West Bengal, 733134, India.
Arindam PaulInstitute of Biological Information Processing (IBI-1), Forschungszentrum Jülich GmbH, 52425, Jülich, Germany.
Harshita ShandInfection and Disease Biology Laboratory, Department of Microbiology, Raiganj University, Raiganj, West Bengal, 733134, India.
Sayan GhosalInfection and Disease Biology Laboratory, Department of Microbiology, Raiganj University, Raiganj, West Bengal, 733134, India.
Suvankar GhoraiInfection and Disease Biology Laboratory, Department of Microbiology, Raiganj University, Raiganj, West Bengal, 733134, India. suvankarbt@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextDengue, a mosquito-borne viral disease endemic to over 100 countries, poses a serious health risk to people living in tropical regions. The viral non-structural proteins NS3 (helicase) and NS5 (RNA-dependent RNA polymerase) are critical targets for antiviral drug development. Several natural and synthetic compounds have been tried against this for the screening of antiviral inhibitor(s) but so far limited success has been achieved. In this study, we have investigated how natural products interact with and destabilize NS3 and NS5. We used in silico methods to screen new potential NS3 and NS5 inhibitors from various anti-cancer flavonoid compounds that previously showed anti-cancer properties in vitro. A virtual screening was conducted on 329 anti-cancer flavonoid compounds, selecting 190 compounds based on Lipinski's rule of five, the Muegge filter, the Ghose filter, and the Veber filter. Molecular docking techniques allowed us to identify Artobiloxanthone (PubChem CID: 46887866) as the most effective binder for NS3, while Glabridin (PubChem CID: 124052) emerged as the most effective binder for NS5. These leading candidates demonstrated favorable ADMET profiles. Additionally, molecular dynamics (MD) simulations of up to 1000-ns showcased stable protein-ligand interactions, with convergence achieved at 200 ns for NS3 and 470 ns for NS5. The structural stability of the complexes was validated by analyzing root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA), and hydrogen bonding (H-bonding). Binding affinity between the ligand and target proteins was further validated by binding free energy calculations using the Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) approach, providing a robust estimation of interaction stability. These findings highlight the potential of Artobiloxanthone and Glabridin as promising inhibitors of dengue virus replication.

methodsThe Chimera v1.11.2 program was employed for protein optimization, while PyRx 0.8 served for molecular docking. Protein structures were converted into.pdbqt format, and ligands were energy-minimized using the MMFF94 force field and conjugate gradient optimization. Visualization was conducted using BIOVIA Discovery Studio Visualizer and PyMOL. The ADMET properties of the top hits were predicted using the pkCSM and ProTox-II platforms. To address missing residues in the crystal structures, AlphaFold2 was used to predict full-length protein models. MD simulations were performed with the GROMACS 2024.5 package, utilizing the AMBER-f99SB-ILDN force field, the TIP3P water model, and a 120 mM NaCl concentration. Equilibration was achieved through V-rescale and C-rescale thermostats, followed by Parrinello-Rahman barostat production runs. Analysis of the MD trajectories included RMSD, RMSF, Rg, SASA, H-bonding, and MM-PBSA utilizing GROMACS tools, gmx_MMPBSA, VMD, and MDAnalysis.

Indexed as

Antineoplastic AgentsAntiviral AgentsDengue VirusFlavonoidsMolecular Docking SimulationViral Nonstructural ProteinsVirus ReplicationHumansMolecular Dynamics SimulationProtein BindingAntineoplastic AgentsAntiviral AgentsFlavonoidsNS5 protein, dengue virusViral Nonstructural ProteinsADMETDengueFlavonoid inhibitorMolecular dockingMolecular simulationNS3-helicaseNS5 RdRp

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.